This decision removes a key obstacle to the medical use of remifentanil, while maintaining all prescribed control measures in accordance with the existing legislation regulating the control of narcotic drugs in Bosnia and Herzegovina. Remifentanil is a potent, short-acting opioid analgesic used in anesthesiology for highly precise pain control. Due to its extremely rapid onset and offset of action, it is particularly useful in demanding anesthesiological procedures, including cardiac and neuroanesthesia, where it enables dynamic and precise pain management tailored to the patient's needs. "By removing the key obstacle to the medical use of remifentanil under strict control, we are raising the standards of safety and quality of healthcare. In European Union member states, remifentanil has long been present in clinical practice as a strictly controlled drug for use in anesthesiology in hospital settings and under a special control regime," emphasized Minister Dubravka Boลกnjak. It is important to recall that the Council of Ministers of BiH, on the proposal of the Ministry of Civil Affairs of BiH, recently adopted an amendment to the List of Narcotic Drugs, thereby removing the fundamental legal obstacle to the medical use of cannabis, with clearly prescribed restrictions limited to pharmaceutical preparations and use based on a medical prescription. Furthermore, after a 14-year delay in updating the List of Narcotic Drugs, the Commission has also harmonized amendments that include the addition of 112 new psychoactive and psychotropic substances, in accordance with the official lists of the International Narcotics Control Board (INCB). These are substances that carry a high risk of overdose, acute intoxication, amnesia, and respiratory depression. Their inclusion enables lawful control and prevention of illegal distribution, as well as a clear legal basis for sanctions. "Given the continuous emergence of new psychoactive substances, it is of particular importance that the legislative framework of Bosnia and Herzegovina remains up-to-date and aligned with international standards," the statement adds.